Merck’s Sotatercept Hits Phase III Marks In Mid-Stage PAH Patients

 
• By Joseph Haas
  
Merck & Co.
Merck shows sotatercept can offer benefit in PAH patients
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D